The hypothesis is that the pretreatment of the HER2+ breast cancer cell line SK-BR-3 with anti-Survivin siRNA will induce apoptosis in the cancer cells and enhance the therapeutic efficacy of DOX, allowing a dose reduction of DOX and hence a reduction of potential side effects. This evidence concerns the gene BIRC5 and cancer.